Influenza Prevention Clinical Trial
Official title:
Multi-center, Randomized, Double-blind, Placebo-controlled Trial of a Live Attenuated Influenza Vaccine in People Aged 3-17
To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine. To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine.
Main end point: Primary influenza protective effect endpoint Protective effect of 14 days on laboratory-confirmed influenza cases. Protective effect of 14 days after receiving lyophilized nasal spray live attenuated influenza vaccine on laboratory-confirmed serotype influenza cases. Secondary endpoints: Secondary point of secondary endpoint Protective effect of freeze-dried nasal spray live attenuated influenza vaccine 0 days later on laboratory-confirmed influenza cases. Protective effect of freeze-dried nasal spray live attenuated influenza vaccine 14 days later on clinically diagnosed influenza cases. Protective effect of live attenuated influenza-like vaccine 14 days against influenza-like cases. safety Incidence of adverse events and serious adverse events within 0-30 days after immunization. Study on detoxification Proproportion of vaccine attenuated proportion and vaccine attenuated content (titer) at different times after vaccination (days 3,7,15). Exploration endpoint: 14 days after the freeze-dried nose vaccine, the vaccine was protective for the detection of COVID-19 cases. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05056519 -
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
|
Phase 1 | |
| Active, not recruiting |
NCT05901636 -
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02713061 -
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants
|
Phase 2 | |
| Not yet recruiting |
NCT05284851 -
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
|
Phase 2 |